293 related articles for article (PubMed ID: 24684961)
1. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
Chen J; Wang J; Zhang Y; Chen D; Yang C; Kai C; Wang X; Shi F; Dou J
J Biosci Bioeng; 2014 Aug; 118(2):214-22. PubMed ID: 24684961
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.
Chen J; Wang J; Chen D; Yang J; Yang C; Zhang Y; Zhang H; Dou J
BMC Cell Biol; 2013 Jan; 14():7. PubMed ID: 23368632
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
5. Stem cell characteristics of dormant cells and cisplatin‑induced effects on the stemness of epithelial ovarian cancer cells.
Zhou N; Wu X; Yang B; Yang X; Zhang D; Qing G
Mol Med Rep; 2014 Nov; 10(5):2495-504. PubMed ID: 25119644
[TBL] [Abstract][Full Text] [Related]
6. The identification of the biological characteristics of human ovarian cancer stem cells.
Yan HC; Fang LS; Xu J; Qiu YY; Lin XM; Huang HX; Han QY
Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3497-503. PubMed ID: 25491627
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
8. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.
Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J
J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895
[TBL] [Abstract][Full Text] [Related]
9. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
[TBL] [Abstract][Full Text] [Related]
10. Cellular characteristics of head and neck cancer stem cells in type IV collagen-coated adherent cultures.
Lim YC; Oh SY; Kim H
Exp Cell Res; 2012 Jun; 318(10):1104-11. PubMed ID: 22426199
[TBL] [Abstract][Full Text] [Related]
11. Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.
Ward Rashidi MR; Mehta P; Bregenzer M; Raghavan S; Fleck EM; Horst EN; Harissa Z; Ravikumar V; Brady S; Bild A; Rao A; Buckanovich RJ; Mehta G
Neoplasia; 2019 Aug; 21(8):822-836. PubMed ID: 31299607
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
13. Lumiflavin increases the sensitivity of ovarian cancer stem-like cells to cisplatin by interfering with riboflavin.
Yang R; Wei Z; Wu S
J Cell Mol Med; 2019 Aug; 23(8):5329-5339. PubMed ID: 31187586
[TBL] [Abstract][Full Text] [Related]
14. Enrichment for chemoresistant ovarian cancer stem cells from human cell lines.
Cole JM; Joseph S; Sudhahar CG; Cowden Dahl KD
J Vis Exp; 2014 Sep; (91):51891. PubMed ID: 25285606
[TBL] [Abstract][Full Text] [Related]
15. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
16. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
17. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
18. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
19. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
20. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
